Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO).
Gianluca Masi
Honoraria - Roche
Fotios Loupakis
No relevant relationships to disclose
Lisa Salvatore
No relevant relationships to disclose
Chiara Cremolini
No relevant relationships to disclose
Lorenzo Fornaro
No relevant relationships to disclose
Marta Schirripa
No relevant relationships to disclose
Cristina Granetto
No relevant relationships to disclose
Emanuela Miraglio
No relevant relationships to disclose
Francesco Di Costanzo
No relevant relationships to disclose
Lorenzo Antonuzzo
No relevant relationships to disclose
Lorenzo Marcucci
No relevant relationships to disclose
Cecilia Barbara
No relevant relationships to disclose
Corrado Boni
No relevant relationships to disclose
Maria Banzi
No relevant relationships to disclose
Silvana Chiara
No relevant relationships to disclose
Daniela Garbarino
No relevant relationships to disclose
Chiara Valsuani
No relevant relationships to disclose
Andrea Bonetti
No relevant relationships to disclose
Luca Boni
No relevant relationships to disclose
Alfredo Falcone
Consultant or Advisory Role - Amgen; Bayer; Merck; Roche
Honoraria - Amgen; Bayer; Merck; Roche
Research Funding - Amgen; Bayer; Merck; Roche